全文获取类型
收费全文 | 402850篇 |
免费 | 17008篇 |
国内免费 | 664篇 |
专业分类
耳鼻咽喉 | 3471篇 |
儿科学 | 12761篇 |
妇产科学 | 7585篇 |
基础医学 | 49302篇 |
口腔科学 | 6981篇 |
临床医学 | 33451篇 |
内科学 | 76454篇 |
皮肤病学 | 4343篇 |
神经病学 | 39051篇 |
特种医学 | 17881篇 |
外国民族医学 | 23篇 |
外科学 | 61265篇 |
综合类 | 3935篇 |
现状与发展 | 1篇 |
一般理论 | 252篇 |
预防医学 | 40219篇 |
眼科学 | 6958篇 |
药学 | 23619篇 |
中国医学 | 975篇 |
肿瘤学 | 31995篇 |
出版年
2023年 | 1008篇 |
2022年 | 1586篇 |
2021年 | 4094篇 |
2020年 | 2786篇 |
2019年 | 4233篇 |
2018年 | 26352篇 |
2017年 | 20864篇 |
2016年 | 23268篇 |
2015年 | 5889篇 |
2014年 | 7956篇 |
2013年 | 10419篇 |
2012年 | 21837篇 |
2011年 | 35815篇 |
2010年 | 26615篇 |
2009年 | 19413篇 |
2008年 | 32655篇 |
2007年 | 35272篇 |
2006年 | 14483篇 |
2005年 | 15433篇 |
2004年 | 15585篇 |
2003年 | 15613篇 |
2002年 | 12912篇 |
2001年 | 5925篇 |
2000年 | 5729篇 |
1999年 | 5344篇 |
1998年 | 3128篇 |
1997年 | 2573篇 |
1996年 | 2335篇 |
1995年 | 2007篇 |
1994年 | 1829篇 |
1993年 | 1681篇 |
1992年 | 3427篇 |
1991年 | 3184篇 |
1990年 | 3023篇 |
1989年 | 2782篇 |
1988年 | 2554篇 |
1987年 | 2257篇 |
1986年 | 2118篇 |
1985年 | 2069篇 |
1984年 | 1567篇 |
1983年 | 1353篇 |
1982年 | 937篇 |
1981年 | 792篇 |
1980年 | 709篇 |
1979年 | 1043篇 |
1978年 | 706篇 |
1977年 | 609篇 |
1974年 | 571篇 |
1973年 | 558篇 |
1972年 | 525篇 |
排序方式: 共有10000条查询结果,搜索用时 437 毫秒
31.
32.
N. S. Hari Narayana Moorthy Sergio F. Sousa Maria J. Ramos Pedro A. Fernandes 《Medicinal chemistry research》2016,25(7):1340-1357
Farnesyltransferase (FTase) is one of the prenyltransferase family enzymes that catalyse the transfer of 15-membered isoprenoid (farnesyl) moiety to the cysteine of CAAX motif-containing proteins including Rho and Ras family of G proteins. Inhibitors of FTase act as drugs for cancer, malaria, progeria and other diseases. In the present investigation, we have developed two structure-based pharmacophore models from protein–ligand complex (3E33 and 3E37) obtained from the protein data bank. Molecular dynamics (MD) simulations were performed on the complexes, and different conformers of the same complex were generated. These conformers were undergone protein–ligand interaction fingerprint (PLIF) analysis, and the fingerprint bits have been used for structure-based pharmacophore model development. The PLIF results showed that Lys164, Tyr166, TrpB106 and TyrB361 are the major interacting residues in both the complexes. The RMSD and RMSF analyses on the MD-simulated systems showed that the absence of FPP in the complex 3E37 has significant effect in the conformational changes of the ligands. During this conformational change, some interactions between the protein and the ligands are lost, but regained after some simulations (after 2 ns). The structure-based pharmacophore models showed that the hydrophobic and acceptor contours are predominantly present in the models. The pharmacophore models were validated using reference compounds, which significantly identified as HITs with smaller RMSD values. The developed structure-based pharmacophore models are significant, and the methodology used in this study is novel from the existing methods (the original X-ray crystallographic coordination of the ligands is used for the model building). In our study, along with the original coordination of the ligand, different conformers of the same complex (protein–ligand) are used. It concluded that the developed methodology is significant for the virtual screening of novel molecules on different targets. 相似文献
33.
34.
Mark Verrill 《Surgery (Oxford)》2019,37(3):181-185
Multimodality primary therapies for breast cancer combined with earlier detection have led to a sharp decline in the death rate from breast cancer in the UK over the last 40 years in the face of a rising incidence. The latest UK statistics from Cancer Research UK report 55,122 new cases of breast cancer in 2015 with 11,563 deaths from breast cancer recorded in 2016. Crudely, this equates to a cure rate of around 80% for all comers and demonstrates a clear improvement in outcome with 50,285 new cases in 2011 and 11,716 deaths in 2012. Despite this good news, there are still significant numbers of women (and men) who suffer from either a local recurrence or metastatic disease following apparently successful treatment for early breast cancer (Stage I to III). Only a minority of individuals, 6.6% with the stage recorded at diagnosis, present with stage IV disease. This review considers the treatment options available to individuals with locally recurrent and advanced breast cancer (ABC). 相似文献
35.
36.
Valerie Iles 《Health care analysis》2016,24(2):105-118
This paper takes a somewhat slant perspective on flourishing and care in the context of suffering, death and dying, arguing that care in this context consists principally of ‘acts of work and courage that enable flourishing’. Starting with the perception that individuals, society and health care professionals have become dulled to death and the process of dying in Western advanced health systems, it suggests that for flourishing to occur, both of these aspects of life need to be faced more directly. The last days of life need to be ‘undulled’. Reflections upon the experiences of the author as carer and daughter in the face of her mother’s experience of death are used as basis for making suggestions about how care systems and professionals might better assist people in dealing with ‘the most grown up thing’ humans ever do, which is to die. 相似文献
37.
38.
39.
40.
William G. Breen Krishan R. Jethwa Nathan Y. Yu Grant M. Spears William S. Harmsen Robert C. Miller Jonathan B. Ashman William G. Rule Terence T. Sio Michelle A. Neben-Wittich Michael G. Haddock Amit Mahipal Mark J. Truty Christopher L. Hallemeier Kenneth W. Merrell 《Practical radiation oncology》2021,11(1):e63-e69
PurposeOur purpose was to determine the effect of chemoradiotherapy (CRT) on patient-reported quality of life (QOL) for patients with intact pancreas cancer.Methods and MaterialsWe reviewed a prospective QOL registry for patients with intact, clinically localized pancreatic ductal adenocarcinoma treated with CRT between June 2015 and November 2018. QOL was assessed pre-CRT (immediately before CRT, after neoadjuvant chemotherapy) and at the completion of CRT with the Functional Assessment of Cancer Therapy-Hepatobiliary (FACT-Hep) and its component parts: FACT-General (FACT-G) and hepatobiliary cancer subscore (HCS). A minimally important difference from pre-CRT was defined as ≥ 6, 5, and 8 points for FACT-G, HCS, and FACT-Hep, respectively.ResultsOf 157 patients who underwent CRT, 100 completed both pre- and post-CRT surveys and were included in the primary analysis. Median age at diagnosis was 65 years (range, 23-90). National Comprehensive Cancer Network resectability status was resectable (3%), borderline resectable (40%), or locally advanced (57%). Folinic acid, 5-fluorouracil, irinotecan, and oxaliplatin (FOLFIRINOX) (75%) or gemcitabine and nab-paclitaxel (42%) were given for a median of 6 cycles (range, 0-42) before CRT. Radiation therapy techniques included 3-dimensional conformal (22%), intensity modulated photon (55%), and intensity modulated proton (23%) radiation therapy to a median dose of 50 Gy (range, 36-62.5). Concurrent chemotherapy was most commonly capecitabine (82%). Sixty-three patients (63%) had surgery after CRT. The mean decline in FACT-G, HCS subscale, and FACT-Hep from pre- to post-CRT was 3.5 (standard deviation [SD], 13.7), 1.7 (SD 7.8), and 5.2 (SD 19.4), respectively. Each of these changes were statistically significant, but did not meet the minimally important difference threshold. Pancreatic head tumor location was associated with decline in FACT-Hep. Nausea was the toxicity with the greatest increase from pre- to post-CRT by both physician-assessment and patient-reported QOL.ConclusionsFor patients with intact pancreatic adenocarcinoma, modern CRT is well tolerated with minimal decline in QOL during treatment. 相似文献